- Home
- ABL vs AUTL Comparison
ABL vs AUTL Comparison
Compare ABL & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABL
- AUTL
- Stock Information
- Founded
- ABL 2004
- AUTL 2014
- Country
- ABL United States
- AUTL United Kingdom
- Employees
- ABL N/A
- AUTL N/A
- Industry
- ABL Investment Managers
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABL Finance
- AUTL Health Care
- Exchange
- ABL Nasdaq
- AUTL Nasdaq
- Market Cap
- ABL 661.9M
- AUTL 625.4M
- IPO Year
- ABL N/A
- AUTL 2018
- Fundamental
- Price
- ABL $6.65
- AUTL $1.27
- Analyst Decision
- ABL Strong Buy
- AUTL Strong Buy
- Analyst Count
- ABL 3
- AUTL 5
- Target Price
- ABL $12.83
- AUTL $9.12
- AVG Volume (30 Days)
- ABL 506.4K
- AUTL 4.4M
- Earning Date
- ABL 11-06-2025
- AUTL 11-11-2025
- Dividend Yield
- ABL N/A
- AUTL N/A
- EPS Growth
- ABL N/A
- AUTL N/A
- EPS
- ABL N/A
- AUTL N/A
- Revenue
- ABL $161,724,466.00
- AUTL $29,934,000.00
- Revenue This Year
- ABL $77.22
- AUTL $641.63
- Revenue Next Year
- ABL $29.93
- AUTL $109.21
- P/E Ratio
- ABL N/A
- AUTL N/A
- Revenue Growth
- ABL 69.56
- AUTL 185.17
- 52 Week Low
- ABL $4.60
- AUTL $1.11
- 52 Week High
- ABL $10.95
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- ABL 56.18
- AUTL 24.20
- Support Level
- ABL $6.20
- AUTL $1.30
- Resistance Level
- ABL $6.80
- AUTL $1.46
- Average True Range (ATR)
- ABL 0.30
- AUTL 0.09
- MACD
- ABL -0.05
- AUTL 0.01
- Stochastic Oscillator
- ABL 45.92
- AUTL 2.63
About ABL Abacus Life Inc.
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company organizes its business into five reportable segments Active Management, Originations, Asset Management, Portfolio Servicing, and Technology Services. Its operations are confined to the United States.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.